FIELD: biotechnology.
SUBSTANCE: anti-B7-H4 antibody or an antigen-binding fragment and its use, a pharmaceutical composition that increases the immune response containing an anti-B7H4 antibody or an antigen-binding fragment, a nucleic acid encoding an antibody or an antigen-binding fragment. Also an expression vector containing a nucleic acid and a host cell for producing an antibody are disclosed.
EFFECT: increasing the immune response in a patient suffering from cancer.
11 cl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTI-B7-H4 ANTIBODY AND DRUG CONJUGATE AND MEDICAL USE THEREOF | 2020 |
|
RU2827531C2 |
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT TUMOUR CONTAINING FUSION PROTEIN CONTAINING IL-2 PROTEIN AND CD80 PROTEIN, AND IMMUNE CONTROL POINT INHIBITOR | 2020 |
|
RU2828377C1 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| POLYFUNCTIONAL PROTEIN MOLECULES CONTAINING DECORIN AND USE THEREOF | 2019 |
|
RU2823357C2 |
| TETRAVALENT SYMMETRICAL BISPECIFIC ANTIBODIES | 2019 |
|
RU2807346C2 |
| ANTIBODY AGAINST B7-H3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL USE | 2018 |
|
RU2765306C2 |
| CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
| ANTIBODIES BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2015 |
|
RU2730674C2 |
